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ABSTRACT  
Objective: The present study was aimed to develop a rapid, specific and sensitive method based on LC-MS/MS method was developed for the 
determination of urocarb using etomidate as an internal standard. 
Methods: Chromatography was achieved on Discovery C18, 50 × 2.1 mm, 5 μm column. Samples were chromatographed in a gradient mode (eluent 
A (acetonitrile-water–formic acid, 5: 95: 0.1 v/v), eluent B (acetonitrile–formic acid, 100: 0.1 v/v)). The initial content of the eluent B of 8%, which 
increases linearly to 1.0 min to 100%, is maintained up to 1.5 min and returned to the original 8% to 1.51 min. The mobile phase was delivered at a 
flow rate of 0.400 ml/min into the mass spectrometer ESI chamber. The sample volume was 4 μl.  
Results: The total chromatographic run time was 2.0 min and the elution of urocarb and IS (etomidate) occurred at ~1.53 and 1.67 min, 
respectively. A linear response function was established at 1-100 ng/ml for urocarb and etomidate in human plasma. The % mean recovery for 
urocarb in LQC, MQC and HQC was 104.1 %, 100.0 % and 97.4 %. The lowest concentration with the RSD<20% was taken as LLOQ and was found to 
be 1.03 ng/ml for urocarb. The within-run coefficients of variation ranged between 0.271 % and 0.478 % for urocarb. The within-run percentages of 
nominal concentrations ranged between 99.12 % and 100.21 % for urocarb. The between-run coefficients of variation ranged between 0.388 % and 
0.601 % for urocarb. The between-run percentages of nominal concentrations ranged between 98.78 % and 101.11 % for urocarb. 
Conclusion: A highly sensitive, specific, reproducible, rapid and high-throughput LC-MS/MS assay was developed and validated to quantify urocarb 
in human plasma as per the regulatory guidelines. Due to the sensitivity of the developed method, it can be applied to the monitoring of plasma 
levels in the analysis of drug in preclinical and clinical pharmacokinetic studies. All the parameters and results were found within the acceptance 
limit as given in the validation protocol. 
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The method development process can be broken down into 
components with a logical progression. In practice, the process is 
more a series of iterative and interlinked steps that may often need 
to be revisited and adjusted to finally arrive at the best method. Fully 
understanding these interdependencies and the requirements 
placed on the assay by these challenges leads to an assay that is fit 
for purpose [1].  
Urocarb (fig. 1) (N-(5-Methyl-[1,3,4]thiadiazol-2-yl)-propionamide)–
the original newly synthesized diuretic, which increased daily 
diuresis in white rats, compared with intact controls, in 2.47 times, 
compared with with hydrochlorothiazide-in 1,6 times and 
acetazolamide-in 1,75 times [2]. When using urocarb, the main 
indicators of general urine analysis remained at the level of healthy, 
intact animals. However, there was a shift in the pH to the weak-
sided side-up to 8.3 units, which is a characteristic pharmacokinetic 
parameter for thiadiazole diuretics–carbonic anhydrase inhibitors 
[3]. The urine specimen of experimental animals in the introduction 
of urocarb was characterized by a significant increase in the 
allocation of Na+ions (p≤0,001) and K +(p≤0,05) and statistically 
insignificant increase in the output of Cl-
 
Fig. 1: Chemical structure of urocarb 
 
Urocarb is an original newly synthesized diuretic. Previously was no 
any bioanalytical method development for urocarb. Therefore, it was 
thought desirable to develop a simple, accurate and fast procedure 
that could be applied for the determination of urocarb in human 
plasma, this study performed assay validations as per guidelines [4-6].  
ions. The level of excretion 
of these electrolytes exceeded the similar indices in the group of 
intact control, but qualitatively and favorably distinguished in 
relation to reference drugs, in particular, the lower level of removal 
of potassium and chloride ions. In this way, urocarb has a high 
diuretic effect and is a low-toxic and non-hepatotoxic compound. 
This implies the possibility of creating on its basis a new diuretic 
drug urocarb. This indicates the promise of this substance for 
further preclinical studies. 
MATERIALS AND METHODS  
Chemicals and reagents  
Urocarb (purity 98.8 %) was synthesized, etomidate (Internal 
Standard) (purity 98.9 %) was purchased from ANEK PRAYOG PVY. 
LTD. (Maharashtra, India), MOEHS CATALANA, S. L., (Barcelona, 
Spain), Zhejiang Huahai Pharmaceutical Co., Ltd (Zhejiang, China), 
EDQM–Council of Europe. HPLC grade acetonitrile and methanol 
were purchased from CHROMASOLV, HPLC grade formic acid was 
purchased from Fluka. All other chemicals and reagents were of 
analytical grade. Microcaps® disposable micropipettes (50 μl, 
catalog number: 1-000-0500) were purchased from Drummond 
Scientific Company, USA. Ultra-pure water was obtained by using a 
MilliQ UF-Plus system (Millipore, Germany); resistivity>18 MΩ. cm-1 







EDTA) plasma sample was 
procured from Red Cross Society, Ukraine.  
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Instrumentation and chromatographic conditions  
A Shimadzu HT (Shimadzu, Japan) LC system equipped with 
degasser (DGU-14A), binary pump (LC-20ADXR) along with auto-
sampler (SIL-20AC HT) was used to inject 5 μl aliquots of the 
processed samples on Discovery C18, 50 × 2.1 mm, 5 μm column 
maintained at 25±1 °C. Samples were chromatographed in a gradient 
mode (eluent A (acetonitrile-water–formic acid, 5: 95: 0.1 v/v), 
eluent B (acetonitrile–formic acid, 100: 0.1 v/v)) [7-8]. Samples 
were chromatographed in gradient mode. The initial content of the 
eluent B of 8%, which increases linearly to 1.0 min to 100%, is 
maintained up to 1.5 min and returned to the original 8% to 1.51 
min (fig. 2). The mobile phase was delivered at a flow rate of 0.400 
ml/min into the mass spectrometer ESI chamber. Parameters of 
electrospray ionizer and MRM parameters are listed in table 1-2. The 
analytical data were processed by Analyst Software (version 1.5.2). 
 
 
Fig. 2: Gradient mode 
 
Table 1: Parameters of ionizer electrospray 
S. No. Parameter Value 
1 Polarity Positive 
2 Nebulizer Gas (NEB, Gas 1) 15 
3 Curtain Gas (CUR) 8 
4 Collision Gas (CAD) 4 
5 IonSpray Voltage (IS) 5000 
6 Temperature (TEM) 400 
7 Turbo IonSpray Gas 8 
8 Horizontal Position 8.0 
9 Lateral Position 2.0 
 
Table 2: Multiple reaction monitoring (MRM) parameters 
ID Parent, m/z Daughter, m/z Time, ms DP, V EP, V CE, V CXP, V 
Urocarb 172.097 116.1 40 16 11 21 20 
Etomidate 245.308 141.2 40 71 11 15 12 
*Abbreviations: DP, declustering potential; FP, focusing potential; EP, entrance potential; CE, collision energy; CXP, collision cell exit potential 
 
Standard solutions  
Urocarb and IS were weighed accurately into volumetric flasks using 
an analytical microbalance. Approximately 1 mg/ml primary stock 
solutions of urocarb and 1 mg/ml primary stock solutions of 
etomidate (IS) solutions were prepared in methanol. The stock 
solutions were stored at −20  °C, which was found to be stable for 1 
mo. The stock solutions of urocarb and etomidate were successively 
diluted with methanol and water to prepare secondary stocks and 
working solutions. Secondary stock solutions and working solutions 
were used to prepare calibration curve (CC) and quality control (QC) 
samples. Working stock solutions were stored at 4 °C for a week. 
Working stocks were used to prepare plasma calibration standards. 
A working IS solution (25 ng/ml) was prepared in acetonitrile: 
methanol (50:50 v/v). Blank human plasma was screened before 
spiking to ensure that it was free from endogenous interference at 
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retention times of urocarb and etomidate, respectively. Calibration 
standards’ samples (1-100 ng/ml for urocarb and etomidate) were 
prepared by spiking the blank human K2EDTA plasma with 
appropriate concentration of urocarb.  
Samples for the determination of precision and accuracy were 
prepared by spiking control human plasma in bulk with urocarb at 
appropriate concentrations (for urocarb 3.00 ng/ml low QC [LQC], 
30.00 ng/ml medium QC [MQC], and 75.00 ng/ml high QC [HQC]) 
and 120 μL plasma aliquots were distributed into different tubes. All 
the samples were stored at −80 °C±10 °C.  
Sample preparation  
A simple protein precipitation extraction method was followed for 
extraction of urocarb at from human plasma. From the deep freezer, 
the required quantities of CC standards and QC samples were with 
drawn. The samples were thawed at room temperature. To an 
aliquot of 100 μl plasma, 20 μl of IS was added. To this mixture, 300 
μl of acetonitrile: methanol (50:50 v/v) was added and vortexed for 
2 min, followed by centrifugation at 6000 rpm for 5 min at 4 °C. After 
centrifugation, approximately 50 μl supernatant was aliquoted into, 
respectively, labeled autosampler vials, which were later placed in 
the autosampler at 15 °C±4 °C. 10 μl of the sample was injected onto 
LC-MS/MS system for analysis. 
Method validation 
A full validation according to the ICH guidelines was performed for 
the assay in K2EDTA human plasma [4]. 
Specificity and selectivity 
The specificity of the method was evaluated by analyzing human plasma 
samples from different lots to investigate the potential interferences at 
the chromatographic peak region for urocarb and IS. The acceptance 
criterion for the experiment was that should have<20% area response to 
that of the LLOQ level response in the same matrix. Two lots of 
hemolyzed plasma samples were also analyzed to ensure specificity 
against potential biological interferences. 
Linearity  
The points CC (1-100 ng/ml) were constructed by plotting the peak 
area ratio of analyte: IS against the nominal concentration of 
calibration standards in K2EDTA human plasma. Following the 
evaluation of different weighing factors, the results were fit into 
linear regression analysis using 1/X2 
The effect of human plasma constituents over the ionization of 
urocarb and IS was determined by post-column infusion method to 
evaluate matrix effect. Briefly, an infusion pump delivers a constant 
amount of analyte into LC system outlet entering to mass 
spectrometer inlet. To follow the analyte signal, the mass 
spectrometer was operated in MRM mode. The human plasma 
constituent sample extract was injected on LC column. A steady ion 
response was obtained as a function of time since the analyte was 
infused at a constant rate. Any endogenous compound that elutes 
from the column which causes a variation in ESI response of the 
infused analyte was seen as a suppression or enhancement in the 
response of the infused analyte. A separate experiment was 
performed with urocarb and IS solutions, which were infused at a 
constant rate, and blank matrix sample injected through the LC. To 
evaluate matrix effect, different lots of human plasma were spiked 
with analyte concentration levels at LQC and HQC levels. According 
to guidelines, the acceptance criterion for each back-calculated 
concentration was±15% deviation from the nominal value. 
Precision and accuracy 
The intra-assay precision and accuracy were estimated by analyzing 
six replicates containing urocarb at four different QC levels in human 
plasma. The four-level QC samples on four different runs were 
performed to assess the interassay precision. The acceptance 
criteria for each back-calculated standard concentration were 85-
115% accuracy from the nominal value except at LLOQ, which was 
set at 80-120%. 
Stability experiments 
Stability tests were conducted to evaluate the stability of urocarb in 
plasma samples under different conditions. 8 h bench top stability, 
processed samples stability (autosampler stability for 26 h at 10 °C), 
three cycles of freeze-thaw stability, 30 d of long-term stability at 
−80±10 °C were performed at LQC and HQC levels using six 
replicates at each level. Samples were considered stable if assay 
values’ acceptance criterion was of accuracy (i.e., 85-115% from 
fresh samples) and precision (i.e.,±15% relative standard deviation 
[RSD]). 
(X: Concentration) weighing 
factor. The CC should have a correlation coefficient (r) of 0.99 or 
better. The acceptance criteria for each back-calculated standard 
concentration were±15% deviation from the nominal value except at 
LLOQ, which was set at±20%. 
Recovery 
The efficiency of urocarb and IS extraction from human plasma was 
determined by comparing the responses of the analytes extracted 
from replicate QC samples (n=6) with those of neat standard 
solutions spiked in post-extracted plasma blank sample at 
equivalent concentrations by protein precipitation extraction 
method. Recovery of urocarb was determined at LQC (3.00 ng/ml) 
and HQC (75.00 ng/ml) concentrations, whereas the recovery of IS 
was determined at a single concentration of 25 ng/ml. 
Matrix effect 
RESULTS AND DISCUSSION 
Urocarb is original newly synthesized diuretic. Aim of our work 
was also to develop rapid, sensitive, and highly selective LC-
MS/MS method for urocarb. The purpose of sample extraction 
optimization is mainly to achieve high extraction recovery with 
negligible or low matrix effects to improve sensitivity and 
reliability of LC-MS/MS analysis [6-12]. A poor extraction 
procedure decreases method robustness due to the presence of 
endogenous interference in the sample extracts, which are not 
efficiently cleaned up due to poor extraction procedure decreases 
the method robustness due to the endogenous interference in the 
sample extracts. With time-saving advantage and simplicity, the 
protein precipitation extraction method was chosen as an 
extraction method. The attained LLOQ was sufficient to quantify 
urocarb in low-dose pharmacokinetic studies. 
For LC system setup, mobile phase, LC column, gradient, flow rate, 
and column temperature are the most commonly adjusted factors 
based on method development time, analysis run time, and expected 
number of samples per day. The purpose of method development is 
to establish a fast, reliable method which can provide clear 
resolution of the analyte. For MS system setup, ion source 
parameters, mass transitions monitored in MRM, and collision cell 
parameters are commonly-adjusted factors based on expected 
analyte concentration and response. The goal of the adjustment is to 
optimize MRM transition response while remaining free of 
interference. 
In the present study, optimization and critical evaluation of mobile 
phase composition (gradient), flow rate, and analytical column were 
important to obtain a good resolution of peaks of interest from the 
endogenous components, which in turn affect reproducibility and 
sensitivity of the method. Selection of chromatographic conditions 
for the proposed method was optimized to suit the preclinical 
pharmacokinetic studies. To ease the sample preparation in 
microtubes and to reduce the usage of solvent, the plasma volume 
was kept low. Initial feasibility experiments of a various mixture(s) 
of solvents such as acetonitrile, methanol and formic acid along with 
altered flow rates (in the range of 0.1-0.6 ml/min) were performed 
to optimize an effective chromatographic resolution of urocarb and 
IS. Various analytical columns were tested to obtained good and 
reproducible response within short run time. The resolution of 
peaks was best achieved with Discovery C18, 50 × 2.1 mm, 5 μm 
column. Samples were chromatographed in a gradient mode (eluent 
A (acetonitrile-water–formic acid, 5: 95: 0.1 v/v), eluent B 
(acetonitrile–formic acid, 100: 0.1 v/v)). The initial content of the 
eluent B of 8%, which increases linearly to 1.0 min to 100%, is 
maintained up to 1.5 min and returned to the original 8% to 1.51 
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min. The mobile phase was delivered at a flow rate of 0.400 ml/min 
into the mass spectrometer ESI chamber. The injection volume was 
4 μl.  
Urocarb eluted at ~1.53 min, respectively. During a direct infusion 
experiment, the mass spectra for urocarb and IS revealed peaks at 
m/z 172.097 and 245.308, respectively as protonated molecular 
ions, [M+H]+. Typical multiple reaction monitoring chromatograms 
of urocarb and internal standard in dipotassium 
ethylenediaminetetraacetic acid human blank plasma are shown in 
fig. 3. 
Specificity 
Different lots of plasma were analysed to ensure that no endogenous 
interferences were present at the retention time of urocarb LLOQ 
level samples along with plasma blank from the respective plasma 
lots were prepared and analysed (table 3). 
Linearity 
The calibration standard curves had a reliable reproducibility over 
the standard concentrations across the calibration range. The 




Fig. 3: Typical multiple reaction monitoring chromatograms of urocarb (left) and internal standard (etomidate) (right) in dipotassium 
ethylenediaminetetraacetic acid human blank plasma, The total chromatographic run time was 2.0 min and the elution of urocarb and IS 
(etomidate) occurred at ~1.53 and 1.67 min, respectively 
 
Table 3: Results of specificity for urocarb 
S. No. Enalapril 
STD BL LLOQ % Interference 
Area RT 
1 0 376 1.53  NIL 
2 0 457 1.52  NIL 
3 0 373 1.52  NIL 
4 0 457 1.53  NIL 
5 0 310 1.53  NIL 
6 0 467 1.53  NIL 
7 0 398 1.53  NIL 
8 0 412 1.53  NIL 
9 0 451 1.52  NIL 
10 0 385 1.53  NIL 
*Average of triplicate injections, In all plasma blanks, the response at the retention time of urocarb was less than 20% of LLOQ response and at the 
retention time of IS, the response was less than 5% of mean IS response in LLOQ.  
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Fig. 4: The calibration curve of urocarb in human plasma 
 
The calibration curve (fig. 4) (peak area ratio Vs Concentration) 
was linear over working range for urocarb of 1 to 100.00 ng/ml 
with 7 point calibration used for quantification by linear 
regression, shown in fig. 4. The regression equation for the 
analysis was 
y=0.00365x+0.000177 with coefficient of correction (r2) = 0.9993. 
Recovery 
The % mean recovery for urocarb in LQC, MQC and HQC are listed in 
table 4. 
 
Table 4: The % mean recovery of urocarb for LQC, MQC and HQC 
S. No. LQC MQC HQC 
1 3.28 30.2 73.5 
2 3.30 32.3 71.9 
3 2.72 28.4 72.3 
4 2.99 29.4 72.2 
5 3.32 29.8 75.2 
Mean 3.12 30.0 73.0 
SD 0.262 1.46 1.36 
% CV 8.4 4.9 1.9 




PAbbreviations: Lower quality control (LQC), middle-quality control 
(MQC), higher quality control (HQC)  
Each value is represented as a mean±SD of 5 observations (n=5), SD: 
Standard Deviation, RSD: Relative Standard Deviation, #Acceptance 
criteria<15 %. 
The % mean recovery for urocarb in LQC, MQC and HQC was 104.1 
%, 100.0 % and 97.4 %. 
Intraday (within run) and Inter-day (between run) precision 
and accuracy 
The within-run coefficients of variation ranged between 0.271 % 
and 0.478 % for urocarb. The within-run percentages of nominal 
concentrations ranged between 99.12 % and 100.21 % for urocarb. 
The between-run coefficients of variation ranged between 0.388 % 
and 0.601 % for urocarb. The between-run percentages of nominal 
concentrations ranged between 98.78 % and 101.11 % for urocarb. 
Results are presented in table 5. 
  
Table 5: Intra-day and Inter-day precision data of urocarb 
Day Intra-day precision Inter-day precision 
 Mean R. S. D % Mean R. S. D % 
1 99.12 0.271 101.11 0.412 
2 100.21 0.478 98.78 0.388 
3 100.18 0.367 100.93 0.601 
*Each value is represented as a mean±SD of observations, SD: Standard Deviation, RSD: Relative Standard Deviation, #Acceptance criteria<15 %., 
The assay values on both the occasions (intra-and inter-day) were found to be within the accepted limits. 
 
Matrix effect 
The lowest concentration with the RSD<20% was taken as LLOQ and 




PAbbreviations: Lower limit of quantification (LLOQ) 
Each value is represented as a mean±SD of 5 observations (n=5), SD: 
Standard Deviation, RSD: Relative Standard Deviation, #Acceptance 
criteria<20 %. 
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The % accuracy of LLOQ samples prepared with the different 
biological matrix lots was found 102.5 %, which were found within 
the range of 80.00-120.00 % for the seven different plasma lots. % 
CV for LLOQ samples was observed as 15.2 %, which are within 
20.00% of the acceptance criteria. 
Stability 
The predicted concentrations for urocarb (3.00 ng/ml and 75.00 
ng/ml) deviated within±15% of the fresh sample concentrations in a 
battery of stability tests namely, in-injector (22 h), bench-top (7 h), 
and repeated four freeze/thaw cycles stability (table 7). 
 
Table 6: Results of matrix effect of urocarb 








% CV 15.2 
% Mean Recovery 102.5 
 
Table 7: Stability data of urocarb at QCs in human plasma 
Nominal concentration (ng/ml) Stability Stability data 
Mean±SD°(n=6) Accuracy (%)• Precision (% CV) 
Urocarb-3.00 0 h 3.12±0.41 99.1 2.56 
7 h (bench-Top) 3.11±0.32 99.8 2.23 
22 h (in-injector) 3.05±0.31 99.2 2.44 
3 FT cycles 3.09±0.26 99.4 2.32 
Urocarb-75.00 0 h 75.8±0.41 99.5 2.12 
7 h (bench-Top) 75.5±0.28 99.1 2.55 
22 h (in-injector) 75.9±0.29 99.3 2.27 
3 FT cycles 75.9±0.38 99.4 3.01 
°Back-calculated plasma concentrations; •Mean assayed concentration/mean assayed concentration at 0 h × 100. FT: Freeze-thaw, SD: Standard 
deviation, QC: Quality control, The results were found to be within the assay variability limits during the entire process. 
 
CONCLUSION 
A highly sensitive, specific, reproducible, rapid and high-throughput 
LC-MS/MS assay was developed and validated to quantify urocarb in 
human plasma as per the regulatory guidelines. The present method 
involved a simple precipitation method of sample preparation, 
which gave consistent and reproducible recoveries. Acquired results 
demonstrate that proposed strategy can be effortlessly and 
advantageously applied for routine examination of urocarb in 
human plasma.  
Due to the sensitivity of the developed method, it can be applied to 
the monitoring of plasma levels in the analysis of drug in preclinical 
and clinical pharmacokinetic studies. All the parameters and results 
were found within the acceptance limit as given in the validation 
protocol. 
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